Integrated Organ Support Therapies Market Size
Integrated Organ Support Therapies Market Size reached US$ 4.11 Billion in 2024 and is expected to reach US$ 6.69 Billion by 2033, growing at a CAGR of 5.6% during the forecast period 2025-2033.
Integrated Organ Support Therapies Market Overview
The integrated organ support therapies market is poised for continued expansion, underpinned by technological innovations (e.g., AI-enabled monitoring), growing critical care demands, and enhanced multi-organ platform adoption. Efforts to reduce device costs, streamline regulatory pathways, and develop portable solutions will further accelerate market penetration, particularly in emerging economies. Innovations in extracorporeal therapies, including ECMO (Extracorporeal Membrane Oxygenation) and CRRT (Continuous Renal Replacement Therapy), have enhanced the efficacy and safety of organ support, leading to increased adoption in intensive care units.
Executive Summary
For more details on this report – Request for Sample
Integrated Organ Support Therapies Market Dynamics: Drivers & Restraints
The rising prevalence of chronic and acute organ failures is significantly driving the integrated organ support therapies market growth
Multi-organ failure is a common consequence of conditions like sepsis, trauma, and severe COVID-19. According to the article published by ScienceDirect, multiple organ failure (MOF) is the cause of 50–80% of all deaths in surgical intensive care units. This rising incidence directly boosts the demand for multi-functional organ support systems such as ADVOS, which can simultaneously support the liver, kidney, and lungs.
Additionally, nearly 750,000 patients per year in the United States and an estimated 2 million patients worldwide are affected by kidney failure. These trends have dramatically raised the need for renal support, especially CRRT in ICUs. Acute and chronic liver failure, often associated with alcoholic liver disease, hepatitis, or drug toxicity (e.g., acetaminophen overdose), necessitate extracorporeal liver support. Devices like MARS (Molecular Adsorbent Recirculating System) and ADVOS have shown improved outcomes in liver detoxification and patient stabilization.
As the global burden of organ failure, whether due to age, chronic disease, or acute illness, increases, hospitals and critical care units are compelled to adopt integrated, multi-organ support systems. This rising clinical need is directly propelling market growth, pushing innovation in combined organ support platforms, and expanding their use beyond traditional single-organ devices.
Risks and complications associated with organ support therapies are hampering the integrated organ support therapies market
One of the most serious complications associated with organ support therapies is the increased risk of infection, especially with invasive devices like extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Many organ support devices, particularly ECMO and CRRT, involve circulating blood outside the body, which further poses a significant risk of blood clot formation or bleeding. These risks may hamper the growth of the market.
Multi-organ support systems are often technologically complex, increasing the risk of device malfunction, calibration errors, and staff mismanagement. This complexity limits use to highly trained centers, restricting broader market penetration. Not all patients benefit from organ support therapies. In cases of irreversible organ damage, therapies like ECMO or CRRT may prolong suffering without improving survival, raising ethical concerns and making clinicians cautious.
Integrated Organ Support Therapies Market Segment Analysis
The global integrated organ support therapies market is segmented based on therapy type, modality, application, end-user, and region.
The multi-organ failure from the application segment is expected to hold 36.54% of the market share in 2024 in the integrated organ support therapies market
Multi-organ failure (MOF) frequently occurs in critically ill patients due to sepsis, trauma, or acute illnesses like COVID-19. It is associated with extremely high ICU mortality rates, often exceeding 50%. These patients require simultaneous support for lungs, kidneys, liver, and sometimes the heart, making them ideal candidates for integrated support platforms.
Patients with failure of two or more organs cannot be managed effectively using single-organ systems alone. Multi-organ platforms like ADVOS (which supports liver, kidney, and lung function) or Baxter’s PrisMax system (which combines CRRT with other blood purification options) are specifically designed to address such complex cases.
Using one integrated system instead of multiple standalone devices for different organs reduces treatment complexity, staffing burdens, and overall cost per patient. Hospitals prefer such platforms when managing patients with MOF to streamline care. Companies are increasingly targeting multi-organ failure as their core use case due to the high unmet need and greater willingness of hospitals to invest in advanced technologies for these critically ill patients.
Integrated Organ Support Therapies Market Geographical Analysis
North America is expected to dominate the global integrated organ support therapies market with a 42.21% share in 2024
The North America region is expected to hold the largest market share over the forecast period, owing to the rising prevalence of chronic diseases and critical illnesses, and high healthcare expenditure. Chronic diseases and critical illnesses are the leading causes of organ failure in the region, especially in the United States, directly driving the need for integrated organ support therapies. Conditions such as cardiovascular diseases, chronic kidney disease (CKD), diabetes, and respiratory diseases significantly increase the incidence of multi-organ failure, where organ support therapies become crucial for patient survival.
Leading global manufacturers such as Baxter International, Medtronic, and Fresenius Medical Care North America are headquartered or have strong operational bases in the U.S. This ensures early access to new products, rapid deployment, and robust after-sales support.
For instance, in February 2025, Vantive, formerly the Baxter Kidney Care segment, launched as a new standalone vital organ therapy company following the completion of its acquisition by funds managed by global investment firm Carlyle from Baxter International Inc. Vantive builds on a 70-year legacy as a leader in kidney care innovation to advance its mission of extending lives and expanding possibilities.
Asia-Pacific is growing at the fastest pace in the Integrated organ support therapies market, holding 21.71% of the market share
Asia-Pacific countries are experiencing a surge in chronic diseases such as diabetes, hypertension, and liver disease, which are major risk factors for organ failure. Additionally, sepsis, trauma, and acute infections continue to drive ICU admissions requiring organ support. Governments in countries like India, Japan, China, and Southeast Asia are investing heavily in upgrading hospital infrastructure, especially intensive care units. This creates a broader base for deploying advanced organ support systems like ECMO, CRRT, and multi-organ platforms.
Medical device companies are increasingly targeting Asia-Pacific for market expansion through local partnerships, manufacturing, and distribution, making technologies more accessible and affordable. For instance, Baxter, Fresenius, and Medtronic have expanded their CRRT and blood purification product lines across Asia through regional offices, training programs, and lower-cost versions adapted for local use.
Integrated Organ Support Therapies Market Top Companies
Top companies in the integrated organ support therapies market include Emulate, Inc., Baxter International, Fresenius Medical Care AG, Getinge AB, LivaNova, Inc., Asahi Kasei Corporation, ADVITOS GmbH, NIHON KOHDEN CORPORATION, Vapotherm, and Fisher & Paykel Healthcare Limited, among others.
Market Scope
Metrics | Details | |
CAGR | 5.6% | |
Market Size Available for Years | 2022-2033 | |
Estimation Forecast Period | 2025-2033 | |
Revenue Units | Value (US$ Bn) | |
Segments Covered | Therapy Type | Extracorporeal Membrane Oxygenation (ECMO), Continuous Renal Replacement Therapy (CRRT), Extracorporeal CO₂ Removal (ECCO₂R), Liver Support Systems, and Cardiac Assist Devices |
Modality | Portable/Transportable Devices, Bedside Devices, and Implantable Devices | |
Application | Respiratory Failure, Cardiac Failure, Liver Failure, Kidney Failure, and Multi-Organ Failure | |
End-User | Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Intensive Care Units (ICUs) | |
Regions Covered | North America, Europe, Asia-Pacific, South America, and the Middle East & Africa | |
The global integrated organ support therapies market report delivers a detailed analysis with 78 key tables, more than 77 visually impactful figures, and 167 pages of expert insights, providing a complete view of the market landscape.
